Company Filing History:
Years Active: 2012-2013
Title: Jorgen Petersen: Innovator in Monoclonal Antibody Research
Introduction
Jorgen Petersen is a prominent inventor based in Rungsted Kyst, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies for cancer treatment. With a total of 4 patents, his work has the potential to impact therapeutic approaches in oncology.
Latest Patents
Petersen's latest patents include innovative methods for treating cancer using human monoclonal antibodies against interleukin 8. These isolated human monoclonal antibodies can be produced in hybridomas, transfectomas, or non-human transgenic animals, such as transgenic mice. The patents also cover pharmaceutical compositions that utilize these antibodies, along with therapeutic and diagnostic methods for their application. Another significant patent involves human monoclonal antibodies targeting the epidermal growth factor receptor (EGFR). Similar to his previous work, these antibodies can be produced through transfectomas or in transgenic animals, and the patents detail related antibody-based compositions and therapeutic methods.
Career Highlights
Jorgen Petersen is associated with Genmab A/S, a leading biotechnology company focused on developing differentiated antibody therapeutics for the treatment of cancer. His expertise in monoclonal antibody technology has positioned him as a key figure in the advancement of cancer therapies.
Collaborations
Petersen has collaborated with notable colleagues in the field, including Ole Baadsgaard and Paul Parren. Their combined efforts have contributed to the innovative research and development of antibody-based treatments.
Conclusion
Jorgen Petersen's work in monoclonal antibody research exemplifies the potential of biotechnology to revolutionize cancer treatment. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.